Literature DB >> 18042805

Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene.

Ji-Long Chen1, Andre Limnander, Paul B Rothman.   

Abstract

The precise mechanisms by which Abl oncogenes transform hematopoietic cells are unknown. We have examined the role of Pim kinases in v-Abl-mediated transformation. In v-Abl transformants, expression of Pim-1 and Pim-2, but not Pim-3, is dependent on Abl kinase activity. Transformation assays demonstrate that v-Abl cannot efficiently transform bone marrow cells derived from Pim-1(-/-)/Pim-2(-/-) mice. Ectopic expression of either Pim-1 or Pim-2 in Pim-1(-/-)/Pim-2(-/-) cells restores transformation by v-Abl, strongly suggesting that either Pim-1 or Pim-2 is required for v-Abl-mediated tumorigenesis. Interestingly, the combined deficiency of Pim-1, Pim-2, and Suppressor of Cytokine Signalling (SOCS)-1 resulted in partial restoration of v-Abl transformation efficiency. In addition, Pim kinases are involved in modification of SOCS-1 and in regulating SOCS-1 protein levels in v-Abl-transformed cells. Furthermore, Pim kinases regulate the proapoptotic proteins Bcl-XS and BAD. Pim kinases inhibit the expression of Bcl-XS. Pim deficiency decreases the phosphorylation levels of BAD, whereas ectopic expression of Pim-1 increases the amount of phospho-BAD. This correlates with an increased protection from apoptosis in Abl transformants expressing Pim kinases. Together, these data suggest that Pim kinases play a key role in the v-Abl transformation, possibly via participating in modulation of SOCS-1 and via regulating the apoptotic signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18042805     DOI: 10.1182/blood-2007-04-083808

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  35 in total

1.  Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation.

Authors:  Shaun Rosebeck; Lisa Madden; Xiaohong Jin; Shufang Gu; Ingrid J Apel; Alex Appert; Rifat A Hamoudi; Heidi Noels; Xavier Sagaert; Peter Van Loo; Mathijs Baens; Ming-Qing Du; Peter C Lucas; Linda M McAllister-Lucas
Journal:  Science       Date:  2011-01-28       Impact factor: 47.728

2.  SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases.

Authors:  Joanne Elliott; Yvonne Suessmuth; Linda M Scott; Krystyna Nahlik; Mary Frances McMullin; Stefan N Constantinescu; Anthony R Green; James A Johnston
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

3.  Pim-2 activates API-5 to inhibit the apoptosis of hepatocellular carcinoma cells through NF-kappaB pathway.

Authors:  Ke Ren; Wei Zhang; Yujun Shi; Jianping Gong
Journal:  Pathol Oncol Res       Date:  2009-10-12       Impact factor: 3.201

Review 4.  The role of Pim kinase in immunomodulation.

Authors:  Zhaoyun Liu; Mei Han; Kai Ding; Rong Fu
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 5.  Why target PIM1 for cancer diagnosis and treatment?

Authors:  Nancy S Magnuson; Zeping Wang; Gang Ding; Raymond Reeves
Journal:  Future Oncol       Date:  2010-09       Impact factor: 3.404

6.  Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.

Authors:  Karin Jöhrer; Marlene Obkircher; Daniel Neureiter; Johanna Parteli; Claudia Zelle-Rieser; Eva Maizner; Johann Kern; Martin Hermann; Frank Hamacher; Olaf Merkel; Nathalie Wacht; Christian Zidorn; Marcel Scheideler; Richard Greil
Journal:  J Mol Med (Berl)       Date:  2011-12-29       Impact factor: 4.599

Review 7.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.

Authors:  Laurent Brault; Christelle Gasser; Franz Bracher; Kilian Huber; Stefan Knapp; Jürg Schwaller
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

Review 8.  At the intersection of DNA damage and immune responses.

Authors:  Jeffrey J Bednarski; Barry P Sleckman
Journal:  Nat Rev Immunol       Date:  2019-04       Impact factor: 53.106

9.  SOCS1, a novel interaction partner of p53 controlling oncogene-induced senescence.

Authors:  Frédérick A Mallette; Viviane Calabrese; Subburaj Ilangumaran; Gerardo Ferbeyre
Journal:  Aging (Albany NY)       Date:  2010-07       Impact factor: 5.682

10.  Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.

Authors:  Alex N Bullock; Santina Russo; Ann Amos; Nicholas Pagano; Howard Bregman; Judit E Debreczeni; Wen Hwa Lee; Frank von Delft; Eric Meggers; Stefan Knapp
Journal:  PLoS One       Date:  2009-10-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.